Current Evidence on Immune-Driven Depression

This review examines immune-driven depression, a major depressive disorder subtype characterized by low-grade inflammation and metabolic disturbances, which shows distinct treatment responses and worse clinical outcomes. Recent evidence includes sex-specific inflammatory associations, novel interventions like GLP-1 agonists and low-dose interleukin-2, and biomarker-guided patient stratification using markers such as hsCRP and motivational anhedonia.